Title	Prospective risk of stillbirth in women with placental mesenchymal dysplasia
Author(s)	Ishikawa, Satoshi; Morikawa, Mamoru; Yamada, Takahiro; Akaishi, Rina; Kaneuchi, Masanori; Minakami, Hisanori
Citation	Journal of obstetrics and gynaecology research, 41(10), 1562-1568 https://doi.org/10.1111/jog.12757
Issue Date	2015-10
Doc URL	http://hdl.handle.net/2115/62921
Rights	This is the peer reviewed version of the following article: Ishikawa, S., Morikawa, M., Yamada, T., Akaishi, R., Kaneuchi, M., and Minakami, H. (2015) Prospective risk of stillbirth in women with placental mesenchymal dysplasia. J. Obstet. Gynaecol. Res., 41: 1562–1568., which has been published in final form at http://dx.doi.org/10.1111/jog.12757 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Type	article (author version)
File Information	manuscript.pdf

[Instructions for use](#)

[ORIGINAL ARTICLE] for JOGR

Title: **Prospective risk of stillbirth in women with placental mesenchymal dysplasia**

Satoshi Ishikawa¹⁾, Mamoru Morikawa¹⁾, Takahiro Yamada^{1)*}, Rina Akaishi¹⁾,
Masanori Kaneuchi²⁾, Hisanori Minakami¹⁾

1) Department of Obstetrics, Hokkaido University Graduate School of Medicine,
Sapporo, Japan

2) Department of Obstetrics and Gynecology, Nagasaki University Graduate School of
Medicine, Nagasaki, Japan

Running head: Prospective risk of stillbirth in PMD

Corresponding author: Takahiro Yamada, MD, PhD,

Department of Obstetrics, Hokkaido University Graduate School of Medicine, N15W7,
Kita-ku, Sapporo, 060-8638, Japan

Tel: +81-11-706-6932; Fax: +81-11-706-6932;

E-mail: taka0197@med.hokudai.ac.jp

Abstract

Aims: To provide better counsel to pregnant women with suspected placental mesenchymal dysplasia (PMD) regarding the risks of preterm birth and intrauterine fetal death (IUFD).

Methods: We reviewed the outcomes of 109 PMD pregnancies with gestational week (GW) ≥ 24 abstracted from 63 reports in the English literature, including two cases that we encountered recently. The prospective risk of stillbirth at GW N was defined as the number of women with stillbirth at GW $\geq N$ divided by number of women giving birth at GW $\geq N$.

Results: A total of 32 (29.4%) women experienced stillbirth at a median GW of 31 (range, 24 – 38). Preterm birth (GW < 37) occurred in 52 (67.5%) of the 77 live-born infants. Only 25 (22.9%) women had full-term (GW ≥ 37) live-born infants. The prospective risks of stillbirth were 29.4% (32/109), 27.5% (25/91), 20.9% (14/67) and 13.0% (6/46) for women who reached GW 24^{-0/7}, 28^{-0/7}, 32^{-0/7} and 36^{-0/7}, respectively.

Conclusion: As women with PMD are at markedly elevated risk of IUFD, early admission to the hospital and intensive monitoring of fetal status should be considered, although whether this policy improves outcome has not been validated.

Key words: antenatal diagnosis, perinatal mortality, placenta, prophylactic treatment, molar pregnancy

39 Introduction

40 As placental mesenchymal dysplasia (PMD) has a distinct placental phenotype,
 41 showing cystic areas mimicking hydatidiform mole on ultrasound, PMD can be
 42 suspected prenatally. However, as PMD can coexist with a completely normal fetus, it
 43 has often been misdiagnosed as a partial hydatidiform mole and has therefore also been
 44 referred to as a “pseudo partial mole”¹⁻³. PMD is extremely rare, occurring in 0.002% –
 45 0.02% of pregnancies^{4,5}, and is seen predominantly in female fetuses⁵.

46 Although PMD is compatible with fetal life, high rates of intrauterine fetal death
 47 (IUFD), i.e., 13% and 36%, were reported in two literature reviews^{6,7}. However, these
 48 reviews^{6,7} did not present “the prospective risk of IUFD” which may be important in
 49 the better counselling among women with living fetuses undelivered, since the
 50 prospective risk of IUFD changes according to gestational week. Preterm delivery
 51 was indicated for severe fetal growth restriction (FGR) and/or non-reassuring fetal
 52 status (NRFS) in several cases. In addition, abrupt worsening of fetal condition was
 53 documented within one day after confirming fetal well-being in at least two cases^{8,9}.
 54 These reports together with the high IUFD rate suggest that delay of delivery causes
 55 IUFD in a considerable number of fetuses affected by PMD. Therefore, intensive
 56 monitoring of women with PMD may improve pregnancy outcome, although this has
 57 not yet been verified.

58 We encountered two women with PMD in whom IUFD occurred at gestational week
 59 (GW) 31 in the first case. We performed an extensive literature search focusing on the
 60 fetal outcome to determine the prospective risk of stillbirth and to provide better

counselling for the second case. Here, we report the prospective risks of stillbirth according to GW among undelivered infants based on the literature search along with our two cases of PMD. Approval for this presentation was obtained from the patient and the Institutional Review Board of the Ethics Committee of Hokkaido University Hospital.

Materials and Methods

This study was conducted with the approval of the institutional review board of Hokkaido University Hospital and conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004). For this study, informed consent was not needed, because this study is a review of the literatures.

A literature search regarding PMD was conducted using PubMed on June 2014. The search term “placental mesenchymal dysplasia” yielded a list of 88 literature reports. Of these, 50 were included in the present analysis because information was available regarding individual data on PMD pregnancies with $GW \geq 24$ in the English language¹⁻⁵⁰. In addition, a further 13 reports⁵¹⁻⁶³ that appeared in reference lists of pertinent literature reports were also included in our analysis. As the first PMD pregnancy was described by Moscoso *et al*⁶⁰ in 1991, we included reports published in 1991 and thereafter. We identified a total of 63 literature reports describing a total of 107 PMD pregnancies with $GW \geq 24$, consisting of 50 dealing with single cases^{3, 4, 6, 8-14, 16-21, 23-36, 38-40, 42-48, 50-52, 54-58, 61, 63}, eight with two cases^{15, 22, 37, 41, 49, 53, 59, 60}, one with

four cases¹, one with five cases⁶², two with nine cases^{2,7}, and one with 14 cases⁵.

These 107 pregnancies in the 63 English literature reports were considered entirely different populations, without double-counting the same individuals with PMD based on maternal age, gestational age, birth weight, fetal gender and/or clinical courses, although some of the data were unknown in some cases (Table 1). In 8^{1,2,5,6,14,15,47,59} of the 63 English literature reports, a total of 14 PMD pregnancies that ended at GW 14 – 23, including two with chromosomal aberrations^{2,5}, were presented, but these pregnancies were excluded from the present analyses.

Finally, we analysed the outcomes of a total of 109 PMD pregnancies, including our two cases focusing on GW at delivery, delivery mode and live birth/stillbirth.

Here, we present a brief summary of our two cases. Case 1: a 27-year-old nulliparous Japanese woman with abnormal findings of the placenta suggestive of PMD on ultrasonography at GW 10 was found to have IUFD at a regular antenatal care on GW 31. A dead, normally formed female infant weighing 1354 g was born at GW 31.

Although no autopsy was performed in this infant, we suspected that anomalies in the placental vasculature were responsible for the IUFD causing hypoxia in this infant.

Case 2: a 26-year-old multiparous Japanese woman at GW 18 was had abnormal findings of the placenta suggestive of PMD on ultrasonography. She underwent caesarean section at GW 31 following long-term (approximately 9 weeks) intensive monitoring of fetal condition and extensive discussion about the risk of IUFD, giving birth to a premature otherwise healthy but FGR female infant weighing 1116 g. The results of histological examination of both placentas for Cases 1 and 2 were consistent

with the diagnosis of PMD showing enlarged, oedematous stem villi with focal cistern formation and large, dilated (to varying degrees) and tortuous vessels on the chorionic plate.

Results

Among 109 PMD pregnancies with $GW \geq 24$, 84 female infants were born, accounting for 77.1% of all 109 infants (Table 1). Median birth weight was 1870 g (range, 185 – 3650 g) for 95 infants with known birth weight. Delivery mode was caesarean section in 31 (52.5%) of 59 women with known delivery mode and live-born infants. The indication for caesarean deliveries was NRFS in 12 (39%)^{16,21,23, 24,31,34,46,47, 49,51,59,63} of the 31 women. Median GW at delivery was 34 (range, 24 – 40) for all 109 women and 36 (24 – 40) for the 77 women with live-born infants. Preterm births at $GW < 37$ occurred in 74.3% of all 109 pregnancies and 67.5% of 77 pregnancies with a live-born infant.

Among 52 preterm deliveries with live-born infants, the NRFS and/or FGR in the absence of premature rupture of the fetal membranes (PROM) were factors leading to preterm deliveries in 11 (21.2%) pregnancies including our Case 2^{6, 7, 18, 34, 46, 47, 49, 51, 56, 59}. Other factors leading to preterm deliveries were PROM in 10 cases^{12, 16, 25, 26, 29, 37, 49, 53, 58, 63} and preterm labour pains in 13 cases^{1, 2, 11, 13,17, 21, 27, 33, 37, 40, 50, 55, 60}.

Only 25 (22.9%) women had full-term ($GW \geq 37$) live-born infants (Fig. 1)^{1-3, 5,7,15,20, 22-24,31,35,39, 42, 45, 52-54, 60, 62}. Of the 25 infants born to these women, including one with an

unspecified birth weight ², 15 (60%) were documented to be born with a low birth weight < 2500 g (6 were less than 2000 g) ^{5, 7, 15, 22-24, 31, 35, 39, 42, 53, 62}.

Stillbirths occurred in 32 (29.4%) women including our Case 1 at median GW of 31 (24 – 38) (Table 1) ^{2, 4, 5, 7-10, 15, 19, 22, 28, 32, 36, 38, 41, 43, 48, 57, 59, 61, 62}. Of 20 infants stillborn at and after GW 30 including our Case 1 (Fig. 1) ^{4, 5, 7-9, 15, 19, 22, 28, 32, 38, 43, 48, 59}, at least 10 infants including our Case 1 exhibited no external anomalies on post-mortem examination ^{4, 7, 9, 32, 38, 43, 48} while 7 infants had anomalies including 13 trisomy in one ¹⁵, Beckwith–Wiedemann syndrome in one ⁵⁹ and a mass arising from the liver in 5; intra-abdominal large cystic mass attached by a pedicle to the inferior side of the liver ⁸, liver cyst ²² and liver cavernous haemangioma ²⁸ in one each, and hepatic mesenchymal hamartoma in two ^{7, 19}. Deaths were considered derived from a decreased maternal–fetal gas exchange due to the placental vascular anomalies in five cases without external anomalies including our Case 1 ^{4, 9, 43, 48}. Rupture of the cirroid chorionic vessels was considered responsible for the IUFD in one ⁴⁸ of the five cases.

Effects of chromosomal aberration and placental size on IUFD rate were examined (Table 2). Although not all of 109 infants with PMD pregnancies underwent chromosomal analysis, three infants ^{15, 28} were identified to have chromosomal aberrations and two of the three were stillborn at GW 30 and GW 36. Both birth weight and placental weight were specified in 82 singleton infants. Median value of the birth weight-to-placental weight ratio (g/g) was 2.10 (range, 0.54 – 5.83) demonstrating that the placenta was large for infant in PMD pregnancies. However, birth weight-to-placental weight ratios (g/g) were not associated with the risks of IUFD

(Table 2).

Prospective risk of stillbirth according to GW was determined (Fig. 2). Women with PMD reaching GW 24 had a prospective risk of stillbirth of 29.4% (32/109). This risk was very high even in women reaching GW 30, 33 and 36, i.e., 24.4% (20/82), 20.0% (12/60) and 13.0% (6/46), respectively.

Discussion

The present literature review focused on the timing of stillbirth among women with PMD and constructed the prospective risk of stillbirth according to GW to provide better counsel to pregnant women with suspected PMD. The prospective risk of stillbirth showed that women with PMD pregnancies had a markedly higher risk of IUFD at any GW of 24 or later. In addition, the present study emphasized that women with PMD were at markedly higher risk of preterm delivery; less than a quarter of women had a full-term live-born infant and 60% of the 25 full-term newborn infants had a low birth weight < 2500 g.

The risk of stillbirth was 29.4% among PMD women who reached GW 24 in this study, far exceeding that of the general population. Stillbirth is rare, accounting for only approximately 0.4% of all births occurring at GW $\geq$ 22 over the past 20 years in Japan⁶⁴, and similar figures have been reported in other areas/countries: 0.47% and 0.28% at and after GW 24 for Inuit and non-Aboriginal residents of Quebec in 2000 – 2009, respectively⁶⁵, and 0.17%, 0.19%, 0.20%, 0.22% and 0.30% at and after GW 32

in 2004 for Finland, Austria, USA, Canada and Italy, respectively⁶⁶. Therefore, women with PMD had a more than 60-fold greater risk of stillbirth than the general population. The prospective risk of stillbirth remained high (above 10%) even in women who reached term of GW 37 at which time the corresponding figure is less than 0.2% in the general Japanese population⁶⁷. Therefore, it is necessary to develop a method to avoid IUFD in women with PMD.

Although causes of IUFD were not known in most cases of PMD pregnancies, dying infants usually show NRFS before death with varying time intervals until death after showing NRFS. Among 52 preterm live-born infants, NRFS and/or FGR were seen in at least 21% of infants, leading to an indicated preterm delivery and the rescue of these infants. Of 20 stillbirths occurring at and after GW 30, 11 of 13 pregnancies with available relevant information^{4, 8, 9, 15, 19, 22, 28, 32, 38, 43, 48, 59} including our Case 1 were managed on an outpatient basis and only two stillbirths occurred during hospital stays; a few hours after admission to a hospital for PROM at GW 34, IUFD occurred following abrupt fetal tachycardia and subsequent prolonged bradycardia despite an emergent caesarean section in one case⁹, and IUFD occurred one day later in another case with normal fetal heart rate pattern on the day of admission to hospital for preterm labour at GW 31⁸. Thus, although the management of PMD pregnancy as an inpatient does not necessarily imply that timely medical intervention can avoid IUFD, we believe that physicians should recommend early hospitalization for women with PMD to allow intensive monitoring of fetal status.

Preterm birth is a major risk factor for increased morbidity and mortality of children.

As an induced vaginal delivery is indicated for infants with IUFD and as IUFD occurred in 29% of PMD pregnancies, the preterm birth rate was expected to be high in women with PMD. However, even after excluding women with IUFD, the preterm birth rate was extremely high in PMD pregnancies; preterm births at GW < 32 and < 37 accounted for 31.2% and 67.5% of all 77 live births (Fig. 1), respectively. The corresponding figures were 0.74% (7768/1050806) and 5.7% (60285/1050806) in Japan in 2011⁶⁸. In these 52 preterm deliveries with live-born infants, NRFS and/or FGR, PROM and preterm labour pains occurred frequently. As PMD pregnancy mimics molar pregnancy with living fetus, the PMD pregnancy may be easily suspected on ultrasound study. Blood flow is seen in placental cysts of PMD pregnancies, while blood flow is absent in the cyst of molar pregnancy⁶⁹. This may help to differentiate PMD pregnancies from molar pregnancies. Recommendation for early prophylactic admission to hospital may be justified to prolong the length of gestation and allow intensive monitoring of fetal condition, although whether this policy is actually beneficial has yet to be verified.

The present study had some limitations. First, the data analysed in this study were based on single case reports and small case series in the literature so publication bias is unavoidable. This may have led to accumulation of eventful pregnancies associated with PMD. Although 29% of fetuses with PMD died in utero in this study, there may have been unreported and uneventful pregnancies with PMD. Therefore, it was possible that this study overestimated the risk of IUFD in pregnancy with PMD. Second, the exact time of IUFD was not specified in most cases. IUFD may have preceded the stillbirth by several days to several weeks. Therefore, figures for the

prospective risk of stillbirth according to GW in this study differed somewhat from those for actual prospective risk of IUFD according to GW.

In conclusion, although it has been noted that IUFD is frequent in PMD pregnancies, the prevalence rate of IUFD reported to date was based on retrospective point of view and was less helpful compared to the prospective risk of stillbirth for clinicians. The prospective risk of stillbirth constructed in this study suggested that a markedly higher risk of stillbirth continued to term among women with PMD. Clinicians encounter PMD women whose fetuses are still alive and have to determine the appropriate management for improving outcome. Our figures for the prospective risk of stillbirth may encourage clinicians to recommend early hospitalization for patients with PMD to allow intensive fetal monitoring. However, whether this policy is beneficial for improving the outcome remains uncertain. Indeed, a case of sudden IUFD in which emergent caesarean section failed to rescue the infant has been reported⁹.

Acknowledgement

This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan (No. 2646246804).

Conflict of interest

All authors declare that they have no financial relationships with biotechnology

- 233 manufacturers, pharmaceutical companies or other commercial entities with an interest
- 234 in the subject matter or materials discussed in this manuscript

References

1. Jauniaux E, Nicolaides KH, Hustin J. Perinatal features associated with placental mesenchymal dysplasia. *Placenta* 1997; 18: 701-6.
2. Paradinas FJ, Sebire NJ, Fisher RA, et al. Pseudo-partial moles: placental stem vessel hydrops and the association with Beckwith-Wiedemann syndrome and complete moles. *Histopathology* 2001; 39: 447-54.
3. Gibson BR, Muir-Padilla J, Champeaux A, Suarez ES. Mesenchymal dysplasia of the placenta. *Placenta* 2004; 25: 671-2.
4. Zeng X, Chen MF, Bureau YA, Brown R. Placental mesenchymal dysplasia and an estimation of the population incidence. *Acta Obstet Gynecol Scand* 2012; 91:754-7.
5. Arizawa M, Nakayama M. Suspected involvement of the X chromosome in placental mesenchymal dysplasia. *Congenit Anom (Kyoto)* 2002; 42: 309-17.
6. Nayeri UA, West AB, Grossetta Nardini HK, Copel JA, Sfakianaki AK. Systematic review of sonographic findings of placental mesenchymal dysplasia and subsequent pregnancy outcome. *Ultrasound Obstet Gynecol* 2013; 41: 366-74.
7. Pham T, Steele J, Stayboldt C, Chan L, Benirschke K. Placental mesenchymal dysplasia is associated with high rates of intrauterine growth restriction and fetal demise: A report of 11 new cases and a review of the literature. *Am J Clin Pathol* 2006; 126: 67-78.

- 254 8. Tortoledo M, Galindo A, Ibarrola C. Placental mesenchymal dysplasia associated
255 with hepatic and pulmonary hamartoma. *Fetal Pediatr Pathol* 2010; 29: 261-70.
- 256 9. Ventura F, Rutigliani M, Bellini C, Bonsignore A, Fulcheri E. Clinical difficulties
257 and forensic diagnosis: histopathological pitfalls of villus mesenchymal dysplasia in
258 the third trimester causing foetal death. *Forensic Sci Int* 2013; 229: e35-41.
- 259 10. Akbarzadeh-Jahromi M, Sari Aslani F, Parvari S. Placental mesenchymal dysplasia
260 complicated by hydrops fetalis and fetal death: a case report. *Arch Iran Med* 2013; 16:
261 551-4.
- 262 11. Ang DC, Rodríguez Urrego PA, Prasad V. Placental mesenchymal dysplasia: a
263 potential misdiagnosed entity. *Arch Gynecol Obstet* 2009; 279: 937-9.
- 264 12. Arigita M, Illa M, Nadal A, et al. Chorionic villus sampling in the prenatal
265 diagnosis of placental mesenchymal dysplasia. *Ultrasound Obstet Gynecol* 2010; 36:
266 644-5.
- 267 13. Aviram R, Kidron D, Silverstein S, et al. Placental mesenchymal dysplasia
268 associated with transient neonatal diabetes mellitus and paternal UPD6. *Placenta* 2008;
269 29: 646-9.
- 270 14. Chan YF, Sampson A. Placental mesenchymal dysplasia: a report of four cases
271 with differentiation from partial hydatidiform mole. *Aust N Z J Obstet Gynaecol* 2003;
272 43: 475-9.
- 273 15. Cohen MC, Roper EC, Sebire NJ, Stanek J, Anumba DO. Placental mesenchymal

- 274 dysplasia associated with fetal aneuploidy. *Prenat Diagn* 2005; 25:187-92.
- 275 16. Francis B, Hallam L, Kecskes Z, Ellwood D, Croaker D, Kent A. Placental
276 mesenchymal dysplasia associated with hepatic mesenchymal hamartoma in the
277 newborn. *Pediatr Dev Pathol* 2007; 10: 50-4.
- 278 17. Furuhashi M, Oda H, Nakashima T. Hydrops of placental stem villi complicated
279 with fetal congenital adrenal hyperplasia. *Arch Gynecol Obstet* 2000; 264:101-4.
- 280 18. Gizzo S, Di Gangi S, Patrelli TS, Saccardi C, D'Antona D, Nardelli GB. Placental
281 mesenchymal dysplasia: can early diagnosis ensure a good materno-foetal outcome? A
282 case report. *Arch Gynecol Obstet* 2012; 286: 15-7.
- 283 19. Harris K, Carreon CK, Vohra N, Williamson A, Dolgin S, Rochelson B. Placental
284 mesenchymal dysplasia with hepatic mesenchymal hamartoma: a case report
285 and literature review. *Fetal Pediatr Pathol*. 2013;32:448-53.
- 286 20. Heazell AE, Sahasrabudhe N, Grossmith AK, Martindale EA, Bhatia K. A case of
287 intrauterine growth restriction in association with placental mesenchymal dysplasia
288 with abnormal placental lymphatic development. *Placenta* 2009; 30: 654-7.
- 289 21. Jalil SS, Mahran MA, Sule M. Placental mesenchymal dysplasia-can it be predicted
290 prenatally? A case report. *Prenat Diagn* 2009; 29: 713-4.
- 291 22. Kaiser-Rogers KA, McFadden DE, Livasy CA, et al. Androgenetic/biparental
292 mosaicism causes placental mesenchymal dysplasia. *J Med Genet* 2006; 43: 187-92.

23. Kinoshita T, Fukaya S, Yasuda Y, Itoh M. Placental mesenchymal dysplasia. J Obstet Gynaecol Res 2007; 33: 83-6.
24. Koga H, Makimura M, Tanaka H, Sumioki H. Placental mesenchymal dysplasia and fetal hematologic disorder. J Pediatr Hematol Oncol 2013 Jun 24. [Epub ahead of print] PubMed PMID: 23799527.
25. Kotani T, Sumigama S, Tsuda H, et al. A case report of placental mesenchymal dysplasia with an increased VEGF-D expression. Placenta 2012; 33: 888-91.
26. Lokan J, Chan YF, Agneta F. Placental mesenchymal dysplasia. Pathology 2002; 34:3 75-8.
27. Matsui H, Iitsuka Y, Yamazawa K, et al. Placental mesenchymal dysplasia initially diagnosed as partial mole. Pathol Int 2003; 53: 810-3.
28. Miliaras D, Conroy J, Pervana S, Meditskou S, McQuaid D, Nowak N. Karyotypic changes detected by comparative genomic hybridization in a stillborn infant with chorioangioma and liver hemangioma. Birth Defects Res A Clin Mol Teratol 2007; 79: 236-41.
29. Morales C, Soler A, Badenas C, et al. Reproductive consequences of genome-wide paternal uniparental disomy mosaicism: description of two cases with different mechanisms of origin and pregnancy outcomes. Fertil Steril 2009; 92: 393.e5-9. doi: 10.1016/j.fertnstert.2009.03.090.
30. Mulch AD, Stallings SP, Salafia CM. Elevated maternal serum alpha-fetoprotein,

- 313 umbilical vein varix, and mesenchymal dysplasia: are they related? Prenat Diagn 2006;
314 26: 659-61.
- 315 31. Ohira S, Ookubo N, Tanaka K, et al. Placental mesenchymal dysplasia:
316 chronological observation of placental images during gestation and review of the
317 literature. Gynecol Obstet Invest 2013; 75: 217-23.
- 318 32. Ohyama M, Kojyo T, Gotoda H, Sato T, Ijiri R, Tanaka Y. Mesenchymal dysplasia
319 of the placenta. Pathol Int 2000; 50: 759-64.
- 320 33. Qichang W, Wenbo W, Liangkai Z, et al. Pregnancy with concomitant
321 chorioangioma and placental mesenchymal dysplasia: a rare placental abnormality.
322 Case Rep Obstet Gynecol 2013;2013:591956.
- 323 34. Reed RC, Beischel L, Schoof J, Johnson J, Raff ML, Kapur RP.
324 Androgenetic/biparental mosaicism in an infant with hepatic mesenchymal hamartoma
325 and placental mesenchymal dysplasia. Pediatr Dev Pathol 2008; 11: 377-83.
- 326 35. Reinhart RD, Wells WA, Harris RD. Focal aneurysmal dilatation of subchorionic
327 vessels simulating chorioangioma. Ultrasound Obstet Gynecol 1999; 13: 147-9.
- 328 36. Robertson M, Geerts LT, de Jong G, Wainwright H. Mesenchymal dysplasia in a
329 monochorionic diamniotic twin pregnancy with review of the differential diagnosis of
330 cystic changes in the placenta. J Ultrasound Med 2007; 26:689-93.
- 331 37. Robinson WP, Lauzon JL, Innes AM, Lim K, Arsovska S, McFadden DE. Origin
332 and outcome of pregnancies affected by androgenetic/biparental chimerism. Hum

- 333 Reprod 2007; 22: 1114-22.
- 334 38. Robinson WP, Slee J, Smith N, et al. Placental mesenchymal dysplasia associated
335 with fetal overgrowth and mosaic deletion of the maternal copy of 11p15.5. Am J Med
336 Genet A 2007;143A:1752-9.
- 337 39. Rohilla M, Siwatch S, Jain V, Nijhawan R. Placentomegaly and placental
338 mesenchymal dysplasia. BMJ Case Rep. 2012 Dec 23; 2012. pii: bcr2012007777.
339 doi:10.1136/bcr-2012-007777.
- 340 40. Ruhland B, Schröer A, Gembruch U, Noack F, Weichert J. Prenatal imaging
341 and postnatal pathologic work-up in a case of fetal hepatic hamartoma and placental
342 mesenchymal dysplasia. Ultrasound Obstet Gynecol 2011; 38: 360-2.
- 343 41. Sheeja S, Usha P, Shiny MP, Renu T. Placental mesenchymal dysplasia: a report of
344 two cases with review of literature. Indian J Pathol Microbiol 2013; 57-9. doi:
345 10.4103/0377-4929.116153.
- 346 42. Starikov R, Goldman R, Dizon DS, Kostadinov S, Carr S. Placental mesenchymal
347 dysplasia presenting as a twin gestation with complete molar pregnancy. Obstet
348 Gynecol 2011; 118: 445-9.
- 349 43. Sudano MC, D'Emidio L, Mangiafico L, Mobili L, Giorlandino C. Placental
350 mesenchymal dysplasia, a case of intrauterine sudden death in a normal-sized fetus. J
351 Prenat Med 2013; 7: 9-11.
- 352 44. Surti U, Hill LM, Dunn J, Prosen T, Hoffner L. Twin pregnancy with a chimeric

- 353 androgenetic and biparental placenta in one twin displaying placental mesenchymal
- 354 dysplasia phenotype. *Prenat Diagn* 2005; 25: 1048-56.
- 355 45. Taga S, Haraga J, Sawada M, Nagai A, Yamamoto D, Hayase R. A case of
- 356 placental mesenchymal dysplasia. *Case Rep Obstet Gynecol* 2013;2013:265159.
- 357 46. Takahashi H, Matsubara S, Kuwata T, et al. Changes in expression of vascular
- 358 endothelial growth factor D-related genes in placental mesenchymal dysplasia. *J*
- 359 *Obstet Gynaecol Res* 2014; 40:1145-9.
- 360 47. Aslan H, Gedikbasi A, Yazarbas K, Yildirim G, Yavuz E. Placental mesenchymal
- 361 dysplasia: a rare clinicopathologic entity confused with molar pregnancy. *J Obstet*
- 362 *Gynaecol* 2013; 33: 246-9.
- 363 48. Umazume T, Kataoka S, Kamamuta K, et al. Placental mesenchymal dysplasia, a
- 364 case of intrauterine sudden death of fetus with rupture of cirroid periumbilical
- 365 chorionic vessels. *Diagn Pathol* 2011; 6: 38. doi: 10.1186/1746-1596-6-38.
- 366 49. Vaisbuch E, Romero R, Kusanovic JP, et al. Three-dimensional sonography of
- 367 placental mesenchymal dysplasia and its differential diagnosis. *J Ultrasound Med*
- 368 2009; 28:359-68.
- 369 50. Woo GW, Rocha FG, Gaspar-Oishi M, Bartholomew ML, Thompson KS.
- 370 Placental mesenchymal dysplasia. *Am J Obstet Gynecol* 2011; 205: e3-5.
- 371 doi:10.1016/j.ajog.2011.08.019.
- 372 51. Alwaidh MH, Woodhall CR, Carty HT. Mesenchymal hamartoma of the liver: a

- 373 case report. *Pediatr Radiol* 1997; 27: 247-9.
- 374 52. Carta M, Maresi E, Giuffrè M, et al. Congenital hepatic mesenchymal hamartoma
375 associated with mesenchymal stem villous hyperplasia of the placenta: case report. *J*
376 *Pediatr Surg* 2005; 40: e37 – 39.
- 377 53. Chen CP, Chern SR, Wang TY, Huang ZD, Huang MC, Chuang CY. Pregnancy
378 with concomitant chorangioma and placental vascular malformation with mesenchymal
379 hyperplasia. *Hum Reprod* 1997; 12:2553-6.
- 380 54. Højberg KE, Aagaard J, Henriques U, Sunde L. Placental vascular malformation
381 with mesenchymal hyperplasia and a localized chorioangioma. A rarity simulating
382 partial mole. *Pathol Res Pract* 1994; 190: 808-13.
- 383 55. Kitano Y, Ruchelli E, Weiner S, Adzick NS. Hepatic mesenchymal hamartoma
384 associated with mesenchymal stem villous hyperplasia of the placenta. *Fetal Diagn*
385 *Ther* 2000; 15: 134-8.
- 386 56. Kuwabara Y, Shima Y, Araki T, Shin S. Mesenchymal stem villous hyperplasia of
387 the placenta and fetal growth restriction. *Obstet Gynecol* 2001; 98: 940 –3.
- 388 57. Laberge JM, Patenaude Y, Desilets V, et al. Large hepatic mesenchymal
389 hamartoma leading to mid-trimester fetal demise. *Fetal Diagn Ther* 2005; 20: 141–145.
- 390 58. Lee GK, Chi JG, Caha KS. An unusual venous anomaly of the placenta. *Am J Clin*
391 *Pathol* 1991; 95: 48-51.

- 392 59. McCowan LM, Becroft DM. Beckwith-Wiedemann syndrome, placental
393 abnormalities, and gestational proteinuric hypertension. *Obstet Gynecol* 1994; 83:
394 813-7.
- 395 60. Moscoso G, Jauniaux E, Hustin J. Placental vascular anomaly with diffuse
396 mesenchymal stem villous hyperplasia. A new clinico-pathological entity? *Pathol Res*
397 *Pract* 1991; 187: 324-8.
- 398 61. Papoutsis D, Mesogitis S, Antonakou A, et al. Partial molar pregnancy with
399 achromosomically and phenotypically normal embryo: presentation of an extremely
400 rare case and review of literature. *J Mater-Fetal Neonat Med* 2011; 24: 1289-93.
- 401 62. Sander CM. Angiomatous malformation of placental chorionic stem vessels and
402 pseudo-partial molar placentas: report of five cases. *Pediatr Pathol* 1993; 13: 621-633.
- 403 63. Takayama M, Soma H, Yaguchi S, et al. Abnormally large placenta associated with
404 Beckwith-Wiedemann syndrome. *Gynecol Obstet Invest* 1986; 22:165-8.
- 405 64. Umazume T, Yamada T, Akaishi R, et al. Essential thrombocythemia as a risk factor
406 for stillbirth. *Thromb Res* 2014; 133: 158–61.
- 407 65. Auger N, Park AL, Zoungrana H, McHugh NG, Luo ZC. Rates of stillbirth by
408 gestational age and cause in Inuit and First Nations populations in Quebec. *CMAJ* 2013;
409 185: E256-62.

- 410 66. Lisonkova S, Sabr Y, Butler B, Joseph KS. International comparisons of preterm
411 birth: higher rates of late preterm birth are associated with lower rates of stillbirth and
412 neonatal death. BJOG 2012; 119: 1630–9.
- 413 67. Minakami H, Izumi A, Tsukahara T, Tamada T. Stillbirth risk in Japan. Lancet
414 1993; 341: 1603-4.
- 415 68. Mother's & Children's Health & Welfare Association. Maternal and child health
416 statistics of Japan, Published by Mother's & Children's Health Organization. 2007,
417 2008, 2009, 2010, 2011, and 2012 editions, Toshihide Ei, Tokyo
- 418 69. Kuwata T, Takahashi H, Matsubara S. 'Stained-glass' sign for placental
419 mesenchymal dysplasia. Ultrasound Obstet Gynecol 2014; 43: 355
- 420
- 421

422 **Figure legends**

423 Fig. 1 Numbers of live-born and stillborn infants according to gestational age

424 Among 109 pregnancies, 32 ended in stillbirth. One case with an unspecified GW at
 425 delivery, but at term⁵⁴, was assumed to give birth at GW 38.

426

427

428

429 Fig. 2 Prospective risk of stillbirth according to gestational week

430 Prospective risk of stillbirth was calculated based on the numbers in Fig. 1 among
 431 women who reached GW N as follows: number of all stillbirths occurring at $GW \geq$
 432 N /number of all births occurring at $GW \geq N$ ⁶⁷.

433

434

Table 1. Demographic characteristics of 109 PMD pregnancies with gestational week ≥ 24

No. of women	109	
Maternal age (year) for 88 women	28 [18 – 39]	
Unknown maternal age	21 (19.3%)	
Parity		
Nulliparity	31 (28%)	
Multiparity	43 (40%)	
Unknown	35 (32%)	
Twin pregnancy	3 (2.8%)	
Infant sex		
Female	84 (77.1%)	
Male	16 (14.7%)	
Unknown	9 (8.3%)	
Birth weight (g) for 95 infants	1870 [185 – 3650]	
– 1499	29 (26.6%)	18 (23.4%)†
1500 – 1999	27 (24.8%)	17 (22.1%)†
2000 – 2499	24 (22.9%)	20 (26.0%)†
2500 – 2999	8 (7.3%)	8 (10.4%)†
3000 –	7 (6.4%)	6 (7.8%)†
Unknown	14 (12.8%)	8 (10.4%)†
Delivery mode for 77 live-born infants		
Cesarean	31 (40.3%)	
Vaginal	28 (36.4%)	
Unknown	18 (23.4%)	
Gestational week at delivery	34 [24 - 40]	36 [24 - 40]†
< 30	27 (24.8%)	15 (19.5%) †
< 34	51 (46.8%)	30 (40.0%)†
< 37	81 (74.3%)	52 (67.5%) †
Stillbirth	32 (29.4%)	
Gestational week at stillbirth	31 [24 - 38]	
24 – 27	7 (21.9%)	
28 – 31	11 (34.4%)	
32 – 35	8 (25.0%)	
36 -	6 (18.8%)	

Data are presented as number of subject (percentage) or median [range].

PMD, placental mesenchymal dysplasia.

†, after excluding 32 cases with stillbirth.

Table 2. Effects of chromosomal aberration and placental size on IUFD rate

Confirmed chromosomal aberration

Present	2/3 (67%)	
Absent or undetermined	30/106 (28%)	<i>P</i> =0.206

Birth weight-to-placental weight ratio (g/g) *

– 1.49	7/29 (24%)	
1.50 – 2.49	8/30 (27%)	
2.50 –	7/23 (30%)	Not significant

*, Both birth weight and placental weight were specified in 82 singleton infants. The IUFD occurred in 22 (27%) of the 82 infants.